Halogenido and carboxylato Ru(II) half-sandwich complexes of the general composition [Ru(η⁶-p-cym)(dpa)X]PF₆ (1-5) were prepared and thoroughly characterized with various techniques (e.g., mass spectrometry, NMR spectroscopy and X-ray analysis); dpa = 2,2'-dipyridylamine; p-cym = p-cymene; X = Cl- (for 1), Br- (for 2), I- (for 3), valproate(1-) (for 4) or 4-phenylbutyrate(1-) (for 5). A single-crystal X-ray analysis showed a pseudo-octahedral piano-stool geometry of [Ru(η⁶-p-cym)(dpa)I]PF₆ (3), with a η⁶-coordinated p-cymene, bidentate N-donor dpa ligand and iodido ligand coordinated to the Ru(II) atom. The results of the ¹H-NMR solution behaviour studies proved that the complexes 1-5 hydrolyse were in the mixture of solvents used (10% MeOD-d₄/90% D₂O). Complexes 1-5 were in vitro inactive against the A2780 human ovarian carcinoma cell line, up to the highest tested concentration (IC50 > 100 μM).

Department of Cell Biology and Genetics and Regional Centre of Advanced Technologies and Materials Faculty of Science Palacký University in Olomouc Šlechtitelů 27 783 71 Olomouc Czech Republic

Department of Inorganic Chemistry and Regional Centre of Advanced Technologies and Materials Faculty of Science Palacký University in Olomouc 17 listopadu 12 771 46 Olomouc Czech Republic

Zobrazit více v PubMed

Murray B.S., Babak M.V., Hartinger C.G., Dyson P.J. The development of RAPTA compounds for the treatment of tumors. Coord. Chem. Rev. 2016;306:86–114. doi: 10.1016/j.ccr.2015.06.014. DOI

Süss-Fink G. Arene ruthenium complexes as anticancer agents. Dalton Trans. 2010;39:1673–1688. doi: 10.1039/B916860P. PubMed DOI

Romero-Canelón I., Salassa L., Sadler P.J. The contrasting activity of iodido versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer complexes: Control of cell selectivity, cross-resistance, p53 dependence, and apoptosis pathway. J. Med. Chem. 2013;56:1291–1300. doi: 10.1021/jm3017442. PubMed DOI

Chiu C.T., Wang Z., Hunsberger J.G., Chuang D.M. Therapeutic potential of mood stabilizers lithium and valproic acid: Beyond bipolar disorder. Pharmacol. Rev. 2013;65:105–142. doi: 10.1124/pr.111.005512. PubMed DOI PMC

Iannitti T., Palmieri B. Clinical and experimental applications of sodium phenylbutyrate. Drugs R&D. 2011;11:227–249. PubMed PMC

Alessio M., Zanellato I., Bonarrigo I., Gabano E., Ravera M., Osella D. Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells. J. Inorg. Biochem. 2013;129:52–57. doi: 10.1016/j.jinorgbio.2013.09.003. PubMed DOI

Kašpárková J., Kostrhunová H., Nováková O., Křikavová R., Vančo J., Trávníček Z., Brabec V. A photoactivatable platinum(IV) complex targeting genomic DNA and histone deacetylases. Angew. Chem. Int. Ed. 2015;54:14478–14482. doi: 10.1002/anie.201506533. PubMed DOI

Novohradsky V., Zerzankova L., Stepankova J., Vrana O., Raveendran R., Gibson D., Kasparkova J., Brabec V. Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands. J. Inorg. Biochem. 2014;140:72–79. doi: 10.1016/j.jinorgbio.2014.07.004. PubMed DOI

Raveendran R., Braude J.P., Wexselblatt E., Novohradsky V., Stuchlikova O., Brabec V., Gandin V., Gibson D. Pt(IV) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action. Chem. Sci. 2016;7:2381–2391. doi: 10.1039/C5SC04205D. PubMed DOI PMC

Romain C., Gaillard S., Elmkaddem M.K., Toupet L., Fischmeister C., Thomas C.M., Renaud J.L. New dipyridylamine ruthenium complexes for transfer hydrogenation of aryl ketones in water. Organometallics. 2010;29:1992–1995. doi: 10.1021/om100127f. DOI

Kaluderović G.N., Krajnović T., Momcilovic M., Stosic-Grujicic S., Mijatović S., Maksimović-Ivanić D., Hey-Hawkins E. Ruthenium(II) p-cymene complex bearing 2,2′-dipyridylamine targets caspase 3 deficient MCF-7 breast cancer cells without disruption of antitumor immune response. J. Inorg. Biochem. 2015;153:315–321. doi: 10.1016/j.jinorgbio.2015.09.006. PubMed DOI

Auzias M., Mattsson J., Therrien B., Süss-Fink G. New dinuclear Ru2(CO)4 sawhorse-type complexes containing bridging carboxylato ligands. Z. Anorg. Allg. Chem. 2009;635:115–119. doi: 10.1002/zaac.200800385. DOI

Stodt R., Gencaslan S., Müller I.M., Sheldrick W.S. Preparation, reactivity and peptide labelling Properties of (η6-arene)ruthenium(II) complexes with pendant carboxylate groups. Eur. J. Inorg. Chem. 2003:1873–1882. doi: 10.1002/ejic.200200599. DOI

Stringer T., Therrien B., Hendricks D.T., Guzgay H., Smith G.S. Mono- and dinuclear (η6-arene) ruthenium(II) benzaldehyde thiosemicarbazone complexes: Synthesis, characterization and cytotoxicity. Inorg. Chem. Commun. 2011;14:956–960. doi: 10.1016/j.inoche.2011.03.041. DOI

Gupta G., Gloria S., Das B., Rao K.M. Study of new mononuclear platinum group metal complexes containing η5 and η6-carbocyclic ligands and nitrogen based derivatives and formation of helices due to N–H···Cl interactions. J. Mol. Struct. 2010;979:205–213. doi: 10.1016/j.molstruc.2010.06.028. DOI

Kumar P., Singh A.K., Pandey R., Li P.Z., Singh S.K., Xu Q., Pandey D.S. Synthesis, characterization and reactivity of arene ruthenium compounds based on 2,2′-dipyridylamine and di-2-pyridylbenzylamine and their applications in catalytic hydrogen transfer of ketones. J. Organomet. Chem. 2010;695:2205–2212. doi: 10.1016/j.jorganchem.2010.06.003. DOI

Kubanik M., Holtkamp H., Sohnel T., Jamieson S.M.F., Hartinger C.G. Impact of the halogen substitution pattern on the biological activity of organoruthenium 8-hydroxyquinoline anticancer agents. Organometallics. 2015;34:5658–5668. doi: 10.1021/acs.organomet.5b00868. DOI

Pouchert C.J. The Aldrich Library of Infrared Spectra (Ed. III) Aldrich Chemical Co.; Milwaukee, WI, USA: 1981.

Govindaswamy P., Mozharivskyj Y.A., Kollipara M.R. Syntheses, spectral and structural studies of Schiff base complexes of η5-pentamethylcyclopentadienyl rhodium and iridium. Polyhedron. 2005;24:1710–1716. doi: 10.1016/j.poly.2005.04.034. DOI

Petruševski G., Naumov P., Jovanovski G., Bogoeva-Gaceva G., Ng S.W. Solid-state forms of sodium valproate, active component of the anticonvulsant drug epilim. ChemMedChem. 2008;3:1377–1386. doi: 10.1002/cmdc.200800112. PubMed DOI

Brittain H.G. Vibrational spectroscopic studies of cocrystals and salts. 3. Cocrystal products formed by benzenecarboxylic acids and their sodium salts. Cryst. Growth Des. 2010;10:1990–2003. doi: 10.1021/cg100099w. DOI

Griffith D.M., Duff B., Suponitsky K.Y., Kavanagh K., Morgan M.P., Egan D., Marmion C.J. Novel trans-platinum complexes of the histone deacetylase inhibitor valproic acid; synthesis, in vitro cytotoxicity and mutagenicity. J. Inorg. Biochem. 2011;105:793–799. doi: 10.1016/j.jinorgbio.2011.03.001. PubMed DOI

Gupta G., Therrien B., Kim J. [Bis-(2-pyrid-yl-κN)amine]chlorido(η6-hexa-methyl-benzene)-ruthenium(II) hexa-fluorido-phosphate dichloro-methane solvate. Acta Cryst. 2011;E67:m548. PubMed PMC

Allen F.H. The Cambridge Structural Database: A quarter of a million crystal structures and rising. Acta Cryst. 2002;B58:380–388. doi: 10.1107/S0108768102003890. PubMed DOI

Betanzos-Lara S., Novakova O., Deeth R.J., Pizarro A.M., Clarkson G.J., Liskova B., Brabec V., Sadler P.J., Habtemariam A. Bipyrimidine ruthenium(II) arene complexes: Structure, reactivity and cytotoxicity. J. Biol. Inorg. Chem. 2012;17:1033–1051. doi: 10.1007/s00775-012-0917-9. PubMed DOI

Sadler P., Morris R., Parsons S., Messenger D. CCDC 276854: Experimental Crystal Structure Determination. CSD Commun. 2005 doi: 10.5517/cc992sf. DOI

Jolley K.E., Clarkson G.J., Wills M. Tethered Ru(II) catalysts containing a Ru–I bond. J. Organomet. Chem. 2015;776:157–162. doi: 10.1016/j.jorganchem.2014.10.033. DOI

Jamieson E.R., Lippard S.J. Structure, recognition, and processing of Cisplatin−DNA adducts. Chem. Rev. 1999;99:2467–2498. doi: 10.1021/cr980421n. PubMed DOI

Morris R.E., Aird R.E., del Socorro Murdoch P., Chen H., Cummings J., Hughes N.D., Parsons S., Parkin A., Boyd G., Jodrell D.I., et al. Inhibition of cancer cell growth by ruthenium(II) arene complexes. J. Med. Chem. 2001;44:3616–3621. doi: 10.1021/jm010051m. PubMed DOI

Štarha P., Hanousková L., Trávníček Z. Organometallic half-sandwich dichloridoruthenium(II) complexes with 7-azaindoles: Synthesis, characterization and elucidation of their anticancer inactivity against A2780 cell line. PLoS ONE. 2015;10:e0143871. PubMed PMC

Reedijk J. Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell? Chem. Rev. 1999;99:2499–2510. doi: 10.1021/cr980422f. PubMed DOI

Wang F., Xu J., Habtemariam A., Bella J., Sadler P.J. Competition between glutathione and guanine for a ruthenium(II) arene anticancer complex: Detection of a sulfenato intermediate. J. Am. Chem. Soc. 2005;127:17734–17743. doi: 10.1021/ja053387k. PubMed DOI

Govender P., Renfrew A.K., Clavel C.M., Dyson P.J., Therrien B., Smith G.S. Antiproliferative activity of chelating N,O- and N,N-ruthenium(II) arene functionalised poly(propyleneimine) dendrimer scaffolds. Dalton Trans. 2011;40:1158–1167. doi: 10.1039/C0DT00761G. PubMed DOI

Makhubela B.C.E., Meyer M., Smith G.S. Evaluation of trimetallic Ru(II)- and Os(II)-arene complexes as potential anticancer agents. J. Organomet. Chem. 2014;772–773:229–241. doi: 10.1016/j.jorganchem.2014.08.034. DOI

Tönnemann J., Risse J., Grote Z., Scopelliti R., Severin K. Efficient and rapid synthesis of chlorido-bridged half-sandwich complexes of ruthenium, rhodium, and iridium by microwave heating. Eur. J. Inorg. Chem. 2013:4558–4562. doi: 10.1002/ejic.201300600. DOI

Gottlieb H.E., Kotlyar V., Nudelman A. NMR chemical shifts of common laboratory solvents as trace impurities. J. Org. Chem. 1997;62:7512–7515. doi: 10.1021/jo971176v. PubMed DOI

Bruker . Apex3. Bruker AXS Inc.; Madison, WI, USA: 2015.

Sheldrick G.M. Crystal structure refinement with SHELXL. Acta Cryst. 2015;C71:3–8. PubMed PMC

Brandenburg K. Diamond Version 4.0.3. Crystal Impact GbR; Bonn, Germany: 2015.

Macrae C.F., Bruno I.J., Chisholm J.A., Edgington P.R., McCabe P., Pidcock E., Rodriguez-Monge L., Taylor R., van de Streek J., Wood P.A. Mercury: Visualization and analysis of crystal structures. J. Appl. Crystallogr. 2008;41:466–470. doi: 10.1107/S0021889807067908. DOI